SciELO - Scientific Electronic Library Online

 
vol.29 issue6Open access, transparency, and quality of information in clinical trialsHistorical reflections on the book Epidemiologia & Saúde: Fundamentos, Métodos, Aplicações author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Cadernos de Saúde Pública

Print version ISSN 0102-311X

Cad. Saúde Pública vol.29 no.6 Rio de Janeiro June 2013

https://doi.org/10.1590/S0102-311X2013000600002 

PERSPECTIVAS PERSPECTIVES

 

Essential medicines and technology incorporation following novel Brazilian Public Health System regulations

 

Nuevos planteamientos de asistencia farmacéutica frente a la regulación de la Ley Orgánica de Salud

 

 

Cláudia Du Bocage Santos-PintoI; Miriam VenturaII; Vera Lúcia Edais PepeI; Claudia Garcia Serpa Osorio-de-CastroI

IEscola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil
IIInstituto de Estudos em Saúde Coletiva, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil

Correspondence

 

 

In Brazil, Law 12,401 of April 2011 1 and Decree 7,508 of June 2011 2 introduced amendments and additions to Law 8,080 of 1990, pertaining to patient care and the incorporation of technologies by the Brazilian Unified National Health System (SUS) and intended to contribute to the implementation of comprehensive care. However, the new legislation appears to have perpetuated the discussions and disagreements on the underlying concepts, guidelines, and principles of comprehensiveness.

The public health experts that formulated SUS suggested "regulated comprehensiveness" based on ethical, scientific, and social premises 3 for establishing equitable access and guaranteeing individual rights in keeping with the population's health needs.

Recent years have witnessed the consecutive enactment and repeal of various rulings and provisions and the realignment of activities in Pharmaceutical Services. Comprehensiveness based on regulations and distinct forms of financing and organization of access have produced greater fragmentation of Pharmaceutical Services, distorted by demand issues and prioritizing the interests of the country's various States, to the detriment of benefits for the citizenry.

Decree 7,508 introduces some prominent measures. These include the National List of Health Actions and Services (RENASES), encompassing all the actions and services supplied by the SUS and specifically defining their scope through continuously updated lists of services and actions. The Decree provides that the user receive a prescription issued by the SUS according to the National List of Essential Medicines (RENAME) and the Clinical Protocols and Treatment Guidelines (PCDT). The medicines are dispensed exclusively within units of the SUS 2, thereby limiting the scope of comprehensiveness to the performance of all stages of care within SUS. Meanwhile, the difficulties in provision of medium- and high-complexity care are well-known; in addition, the incorporation of technologies per se, without articulated action between the hierarchical levels, has a limited impact in terms of improving access 4.

In this context, the configuration of the RENAME is a central point in the debate. Lists of essential medicines have been adopted worldwide, elaborated according to the concept of essential medicines proposed by the World Health Organization (WHO) since 1977. Such lists are the key to all administration of Pharmaceutical Services. They provide the structural basis for other actions, such as forecasting, organization of financing, procurement, logistics, and the actual use of medicines. Since 1997, Brazil had been formulating an evidence-based list of essential medicines according to the National Medicines Policy (PNM) and the National Policy for Pharmaceutical Care (PNAF). The penultimate versions of the RENAME (2000, 2002, 2006, 2008, and 2010) were developed on the basis of a comparative evaluation of efficacy, effectiveness, safety, convenience, and cost of medicines for the country's priority health conditions. These editions contained an average of 350 medicines. The RENAME included medicines for low, medium, and high complexity of care that represented the best options for first and second line treatments. The list was also an important management tool, and it was recommended for adoption and possible adaptation and/or complementation by States or Municipalities concerned with providing the best possible pharmaceutical services for their inhabitants.

However, the RENAME list recently reemerged with a completely reformulated concept and composition. Ministry of Health Ruling 533 of March 28, 2012 5 redefines it as a single list comprising the components of financing of pharmaceutical services (combining all the items from all the Ministry of Health's programs and actions, many of which were not evidence-based), totaling 810 items, all of which were termed as "essential" by the Ruling.

This type of list is subject to constant stress, both by pressure from the growing market of new health technologies and political opportunities for supplying medicines that are frequently the object of court cases, with a dubious risk/benefit profile. This scenario was already visible in the States and Municipalities when the wave of individual court cases began to fuel the acritical addition of technologies to government funded lists 6. From the public health point of view, none of these factors legitimizes the hasty or abusive incorporation of medicines by SUS.

The National Commission on the Incorporation of Technologies by the National Health System (CONITEC) was created by Law 12,401 and has been in operation since mid-2012. As of February 27, 2013, the Commission had received 114 petitions for the inclusion or expansion of technologies by the National Health System. As of that date, the Commission had issued 30 rulings and incorporated 30 medicines (CONITEC. http://portal.saude.gov.br/portal/saude/Gestor/area.cfm?id_area=1611, accessed on 28/Feb/2013). As far as we could ascertain, there have been no efforts to review the 810 medicines in the current "RENAME" list, many of which are inappropriate for supply by the SUS.

Considering that States already experienced difficulty in managing a list of 350 essential medicines, the 810 medicines in the new "RENAME" list (plus those that will likely be added in the future) will prove even more problematic. Given the pace of incorporation of new technologies (many of them high-cost), it is important to emphasize that when SUS defends the principle of comprehensiveness in pharmaceutical services, the system should safeguard its own long-term sustainability. It is necessary to adopt a single list of essential medicines based on evidence and legitimized by national needs, adhered to by prescribers and health managers and acknowledged by the population as effective, in contrast to the positive list for financing, consisting of various new technologies and medicines that fail to meet the definition of essentiality.

The adoption of an amalgam of countless government funded lists (like the current "RENAME" list) that have appeared and taken hold in recent years represents a step backward, fostering the logic of financed supply as a substitute for the logic of priority-based needs.

Comprehensiveness can still be a useful and ethical concept for identifying desirable values and characteristics for the health system 7, as long as it refers to access by all citizens to low-, medium-, and high-complexity procedures and pharmaceuticals and health products. Such access should not be ensured merely by political convenience, but through a socially negotiated process. It is urgent to revise the concept of comprehensiveness currently permeating Pharmaceutical services and SUS, since it has materialized and perpetuated itself not as a virtuous principle, but as a problem running contrary to the population's health priorities.

 

Contributors

C. D. B. Santos-Pinto contributed to the conceptualization of the theme, the literature review, and the writing and revision of the article. M. Ventura and V. L. E. Pepe contributed to the writing and revision of the article. C. G. S. Osorio-de-Castro contributed to the conceptualization of the theme and writing and revision of the article.

1. Brasil. Lei nº 12.401, de 28 de abril de 2011. Altera a Lei nº 8.080, de 19 de setembro de 1990, para dispor sobre a assistência terapêutica e a incorporação de tecnologia em saúde no âmbito do Sistema Único de Saúde – SUS. Diário Oficial da União 2011; 29 abr.         [ Links ]

2. Brasil. Decreto nº 7.508, 28 de junho de 2011. Regulamenta a Lei nº 8.080, de 19 de setembro de 1990, para dispor sobre a organização do Sistema Único de Saúde – SUS, o planejamento da saúde, a assistência à saúde e a articulação interfederativa, e dá outras providências. Diário Oficial da União 2011; 29 jun.         [ Links ]

3. Conselho Nacional de Secretários de Saúde. SUS: avanços e desafios. Brasília: Conselho Nacional de Secretários de Saúde; 2006.         [ Links ]

4. Spedo SMP, Nicanor RS, Tanaka OU. O difícil acesso a serviços de média complexidade do SUS: o caso da cidade de São Paulo, Brasil. Physis (Rio J.) 2010; 20:953-72.         [ Links ]

5. Ministério da Saúde. Portaria nº 533 de 28 de março de 2012. Estabelece o elenco de medicamentos e insumos da Relação Nacional de Medicamentos Essenciais (RENAME) no âmbito do Sistema Único de Saúde (SUS). Diário Oficial da União 2012; 29 mar.         [ Links ]

6. Machado MAA, Acurcio FA Brandão CMR, Faleiros DR, Guerra Jr. AA, Cherchiglia ML, et al. Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil. Rev Saúde Pública 2011; 45:590-8.         [ Links ]

7. Mattos RA. A integralidade na prática (ou sobre a prática da integralidade). Cad Saúde Pública 2004; 20:1411-6.         [ Links ]

 

 

Correspondence
C. D. B. S. Pinto
Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
Rua Leopoldo Bulhões 1480, sala 632
Rio de Janeiro, RJ 21041-210, Brasil
clabocage@hotmail.com

Submitted on 06/Mar/2013
Approved on 27/Mar/2013

 

 

A versão em inglês deste texto está disponível online no Portal SciELO (http://www.scielo.br/csp).
The English version of this text is available online in the SciELO (http://www.scielo.br/csp).
La versión en Inglés de este texto está disponible en línea en el SciELO (http://www.scielo.br/csp).

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License